Pyxis Oncology (PYXS) Cost of Revenue (2024 - 2025)

Pyxis Oncology (PYXS) reported Cost of Revenue of $2.4 million for Q4 2025, up 402.74% quarter-over-quarter from $475000.0 in Q1 2024.

Pyxis Oncology (PYXS) Cost of Revenue (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has 2 years of Cost of Revenue data on file, last reported at $2.4 million in Q4 2025.

Cost of Revenue for Q4 2025 came in at $2.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $2.4 million (up 402.74% YoY), and the FY2025 annual result was $2.4 million, up 402.74% from the prior year.
Cost of Revenue improved to $2.4 million in Q4 2025 per PYXS's latest filing, from $475000.0 in the prior quarter.
Over five years, Cost of Revenue peaked at $2.4 million in Q4 2025 and troughed at $475000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	64.20 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	48,670.00
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	392.80 Mn
9	Abivax	91.96 Bn	91.96 Bn	-	2.05 Mn
10	Pyxis Oncology	125.84 Mn	108.95 Mn	8.65 Mn	2.39 Mn

Download Data